Intraoperative packed red blood cell transfusion (iPRBT) and PCI-normalised iPRBT rates (iPRBT/PCI ratio) negatively affect short- and long-term outcomes of patients undergoing cytoreductive surgery and intraperitoneal chemotherapy – An analysis of 880 patients

Fisher, Oliver M.; Alzahrani, Nayef; Kozman, Mathew A.; Valle, Sarah J.; Morris, David L.

doi:10.1016/j.ejso.2019.07.031

Cited by 7 publications

(2 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This level of blood loss equated to a haemoglobin drop from 116 ± 4 g/L to 64 ± 13 g/L. There was no discussion about blood loss in the paper by van Driel et al or Farrell et al 7,19 In a study of 880 patients undergoing interval CRS and HIPEC by Fisher et al, 21 intra‐operative PRBC transfusions of >5 units was found to worsen long‐term patient mortality and morbidity. Our mean transfusion rate was 3 ± 1 units.…”

Section: Discussionmentioning

confidence: 99%

Safety and feasibility of hyperthermic intraperitoneal chemotherapy during interval cytoreductive surgery in patients with advanced high‐grade serous ovarian, fallopian tube, peritoneal cancer in an Australian context

Samoylovich,

Jennings,

Shannon

et al. 2023

Aust NZ J Obst Gynaeco

View full text Add to dashboard Cite

AimsTo assess the safety and feasibility of hyperthermic intraperitoneal chemotherapy (HIPEC) during cytoreduction surgery (CRS) in advanced high‐grade serous ovarian, fallopian tube and peritoneal cancer within an Australian context.MethodsData were collected from 25 consecutive patients undergoing CRS and HIPEC from December 2018 to July 2022 at the Peritoneal Malignancy Service at the Mater Hospital Brisbane, Australia. Data collected included demographics, clinical variables, surgical procedures and complications and intra‐operative and post‐operative indexes of morbidity.ResultsTwenty‐five women who underwent CRS and HIPEC from December 2018 to July 2022 were included in analysis. Findings indicate that CRS with HIPEC is associated with low morbidity.ConclusionWhile judicious patient selection is imperative, HIPEC during CRS was well tolerated by all patients and morbidity was comparable to results from the previously reported OVHIPEC‐1 trial. HIPEC appears to be a safe and feasible addition to CRS for the treatment of advanced ovarian cancer in Australian practice.

show abstract

Section: Discussionmentioning

confidence: 99%

Safety and feasibility of hyperthermic intraperitoneal chemotherapy during interval cytoreductive surgery in patients with advanced high‐grade serous ovarian, fallopian tube, peritoneal cancer in an Australian context

Samoylovich,

Jennings,

Shannon

et al. 2023

Aust NZ J Obst Gynaeco

View full text Add to dashboard Cite

show abstract

“…The lack of data on the number of blood transfusions is a major drawback of our study unfortunately. Since they may negatively impact perioperative and long-term outcomes of patients, sparing protocols are advisable [ 22 , 25 , 27 , 43 , 58 , 59 , 60 ].…”

Section: Discussionmentioning

confidence: 99%

Complications and Mortality Rate of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy: Italian Peritoneal Surface Malignancies Oncoteam Results Analysis

Carboni

Valle

Vaira

et al. 2022

Cancers

View full text Add to dashboard Cite

Background: Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy may significantly improve survival for selected patients with peritoneal surface malignancies, but it has always been criticized due to the high incidence of postoperative morbidity and mortality. Methods: Data were collected from nine Italian centers with peritoneal surface malignancies expertise within a collaborative group of the Italian Society of Surgical Oncology. Complications and mortality rates were recorded, and multivariate Cox analysis was used to identify risk factors. Results: The study included 2576 patients. The procedure was mostly performed for ovarian (27.4%) and colon cancer (22.4%). The median peritoneal cancer index was 13. Overall postoperative morbidity and mortality rates were 34% and 1.6%. A total of 232 (9%) patients required surgical reoperation. Multivariate regression logistic analysis identified the type of perfusion (p ≤ 0.0001), body mass index (p ≤ 0.0001), number of resections (p ≤ 0.0001) and colorectal resections (p ≤ 0.0001) as the strongest predictors of complications, whereas the number of resections (p ≤ 0.0001) and age (p = 0.01) were the strongest predictors of mortality. Conclusions: Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy is a valuable option of treatment for selected patients with peritoneal carcinomatosis providing low postoperative morbidity and mortality rates, if performed in high-volume specialized centers.

show abstract

Perioperative Blood Transfusions and Cancer Progression: A Narrative Review

Abou Daher,

Heppell,

Lopez-Plaza

et al. 2024

Curr Oncol Rep

View full text Add to dashboard Cite

Intraoperative packed red blood cell transfusion (iPRBT) and PCI-normalised iPRBT rates (iPRBT/PCI ratio) negatively affect short- and long-term outcomes of patients undergoing cytoreductive surgery and intraperitoneal chemotherapy – An analysis of 880 patients

Cited by 7 publications

References 38 publications

Safety and feasibility of hyperthermic intraperitoneal chemotherapy during interval cytoreductive surgery in patients with advanced high‐grade serous ovarian, fallopian tube, peritoneal cancer in an Australian context

Safety and feasibility of hyperthermic intraperitoneal chemotherapy during interval cytoreductive surgery in patients with advanced high‐grade serous ovarian, fallopian tube, peritoneal cancer in an Australian context

Complications and Mortality Rate of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy: Italian Peritoneal Surface Malignancies Oncoteam Results Analysis

Perioperative Blood Transfusions and Cancer Progression: A Narrative Review

Contact Info

Product

Resources

About